AmBisome (Amphotericin B) Liposome

DRUG2 trials

Sponsors

Aurobindo Pharma Ltd, Beijing Friendship Hospital

Conditions

Invasive Mold DiseasesVisceral Leishmaniasis

Phase 1

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

CompletedNCT03636659

Aurobindo Pharma LtdVisceral Leishmaniasis

Start: 2018-05-02End: 2019-04-05Updated: 2019-08-26

Unknown Phase

Safety and Efficacy of Liposomal Amphotericin B for Patients With Invasive Mold Diseases in Liver Transplant Recipients

Not yet recruitingNCT07725874

Beijing Friendship HospitalInvasive Mold Diseases

Start: 2026-08-08End: 2028-08-15Target: 60Updated: 2026-07-24